NCT06437041 is a NA clinical trial of Ornidazole in Irritable Bowel Syndrome, sponsored by Faming Zhang.

Who is sponsoring NCT06437041?

NCT06437041 is sponsored by Faming Zhang.

What drugs are being tested in NCT06437041?

Interventions in NCT06437041: Ornidazole, Placebo.

What condition does NCT06437041 study?

NCT06437041 studies Irritable Bowel Syndrome.

Is NCT06437041 still recruiting?

NCT06437041 is currently not yet recruiting. Last updated 24 May 2024.

Last reviewed 2024-05-24 · How we verify

NCT06437041

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Antibiotic Pretreatment on the Efficacy of WMT in the Treatment of Irritable Bowel Syndrome in Adults: a Multi-center, Randomized, Placebo-controlledClinical Study

Not yet recruiting NA Last updated 24 May 2024

What this trial tests

NA trial testing Ornidazole in Irritable Bowel Syndrome in 96 participants. Not yet recruiting.

Timeline

1 June 2024

Primary endpoint
31 December 2029

31 March 2030

Quick facts

Lead sponsor	Faming Zhang
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	96
Start date	1 June 2024
Primary completion	31 December 2029
Estimated completion	31 March 2030
Sites	1 location across China

Drugs / interventions tested

Ornidazole (ORNIDAZOLE) — full drug profile →
Placebo

Conditions studied

Irritable Bowel Syndrome — all drugs for Irritable Bowel Syndrome →

Sponsor

Faming Zhang

Who can join

18 and older, any sex, with Irritable Bowel Syndrome. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Gastrointestinal Symptoms Rating Scales（GSRS）
Time frame: One-week, Four-week and Eight-week post-WMT
Gastrointestinal Symptom Rating Scale (GSRS) included 5 items: abdominal pain (3 items), reflux (2 items), dyspepsia (4 items), diarrhea (3 items) and constipation (3 items). The severity of each symptom was assessed using a 4-point Likert scale, with a score of 0 indicating no symptoms and a score of 3 indicating very severe symptoms.
IBS Symptom Severity Scaleand(IBS-SSS)
Time frame: One-week, Four-week and Eight-week post-WMT
IBS symptom severity scale (IBS-SSS) consists of five items, which assess the severity of abdominal pain, the frequency of abdominal pain, the degree of abdominal distention and discomfort, the satisfaction of bowel habit and behavior, and the impact of intestinal symptoms on life. Each item was divided into 5 levels, increasing by 20 points, and the total score was 500 points. A score of 75 to 17

Sponsor's own description

This is a randomized controlled trial to explore the efficacy of antibiotic pretreatment on the efficacy of WMT in the treatment of Irritable bowel syndrome in adults: a multi-center, randomized, placebo-controlled clinical study

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Irritable Bowel Syndrome

Currently open trials in the same condition.

NCT07235228 — Effects of Vivatlac Synbiotic on Gut Micribiota of IBS Patients · NA · recruiting
NCT07421011 — Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 · Phase 1 · recruiting
NCT07360938 — Drug Interaction Potential of Pro-Inflammatory Conditions · recruiting
NCT06788444 — Efficacy of Esketamine for Patients With Irritable Bowel Syndrome · NA · recruiting
NCT07484412 — Efficacy and Safety of Encapsulated Bifidobacterium Longum BBH016 in Subjects With Lower Gastrointestinal Symptoms · NA · active not recruiting

Other Faming Zhang trials

Trials by the same sponsor.

NCT04169152 — CAES for Internal Hemorrhoids and Rectal Prolapse · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06437041 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Faming Zhang
Last refreshed: 24 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06437041.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing